Free Trial
NASDAQ:PRE

Prenetics Global 10/6/2025 Earnings Report

Prenetics Global logo
$9.39 +1.30 (+16.07%)
Closing price 04:00 PM Eastern
Extended Trading
$8.98 -0.42 (-4.42%)
As of 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prenetics Global EPS Results

Actual EPS
N/A
Consensus EPS
-$0.71
Beat/Miss
N/A
One Year Ago EPS
N/A

Prenetics Global Revenue Results

Actual Revenue
N/A
Expected Revenue
$21.70 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Prenetics Global Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Prenetics Global Earnings Headlines

This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
PRE Prenetics Global Limited - Seeking Alpha
See More Prenetics Global Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prenetics Global? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prenetics Global and other key companies, straight to your email.

About Prenetics Global

Prenetics Global (NASDAQ:PRE) (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America. Its consumer brand, CircleDNA, offers a direct-to-consumer genetic testing kit that reports on wellness traits, nutrition, fitness and inherited disease risks. On the corporate side, the company partners with healthcare providers, sports organizations and governments to deploy large-scale testing programs and personalized health initiatives. Prenetics also supports telehealth services, enabling remote consultations based on genetic and diagnostic results.

Founded in 2014 and headquartered in Hong Kong, Prenetics was established by CEO Danny Yeung, a tech entrepreneur with a background in fintech and digital platforms. Under his leadership, the company has expanded through strategic partnerships and investments in laboratory automation and data analytics. Prenetics completed a public listing on the Nasdaq in 2022, positioning itself to accelerate global market expansion and further develop its precision health offerings.

View Prenetics Global Profile

More Earnings Resources from MarketBeat